Zomig was approved to treat migraine and cluster headache in the EU. It is available in three formulations, including oral tablet, orally dispersible tablet and nasal spray.
Under the deal, AstraZeneca will secure $200m from Grünenthal upon completion. AstraZeneca is also eligible to receive up to an additional $102m in future milestone payments.
Grünenthal will hold rights to Zomig in all market outside Japan, including the US. Impax Pharmaceuticals will continue to market Zomig in the US on behalf of the Grünenthal.
During a transition period, AstraZeneca will continue to produce and supply the medicine.
Subject to regulatory clearances, the deal is expected to complete before the end of the second quarter this year.
Grünenthal CEO Gabriel Baertschi said: “Migraine is a very debilitating disease with more than 75 million people worldwide suffering from attacks that can lead to sensitivity to light or sound, to nausea or even vomiting.
“The acquisition of the well-established Zomig products complements our existing pain portfolio.”
AstraZeneca global product and portfolio strategy executive vice president Mark Mallon said: “Grünenthal is an established partner with expertise in the treatment of pain. It is well placed to ensure patients continue to benefit from Zomig, and to extend the commercial potential of the medicine through its dedicated salesforce.”
Image: Zomig migraine treatment is available in oral tablet, orally dispersible tablet and nasal spray formulations. Photo: courtesy of AstraZeneca.